

Anti-BLyS/APRIL Antibody (Telitacicept)

Introduction

Telitacicept is a bispecific fusion protein developed by a Chinese biopharmaceutical company, mainly composed of TACI (transmembrane activator and calmodulin interacting molecule) and IgG Fc fragment. Its mechanism is to inhibit the excessive activation of B cells by binding BLyS (B cell activating factor) and APRIL (proliferation inducing ligand), so as to treat autoimmune diseases such as systemic lupus erythematosus.

Product parameters

Alternative Names	RC18
Target Accession	-
Target	BLyS/APRIL
CAS number	2136630-26-5
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

